<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998061</url>
  </required_header>
  <id_info>
    <org_study_id>ZhejiangU</org_study_id>
    <nct_id>NCT01998061</nct_id>
  </id_info>
  <brief_title>Continuation of TKI With or Without Chemotherapy Beyond Gradual Progression</brief_title>
  <official_title>Phase II Study of Continuation of Tyrosine Kinase Inhibitor (TKI) With or Without Chemotherapy Beyond Gradual Progression in Advanced Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There have been reports suggesting that continuous administration of epidermal growth factor&#xD;
      receptor-tyrosine kinase inhibitors (EGFR-TKIs) is advantageous for patients in which gradual&#xD;
      disease progression was observed after the establishment of clinical benefit from EGFR-TKIs.&#xD;
      However, whether EGFR TKI with or without chemotherapy provides more survival benefit has not&#xD;
      been formally evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We design this clinical trial to compare the efficacy of continuation of EGFR TKI with or&#xD;
      without chemotherapy in patients beyond gradual progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate cacy</measure>
    <time_frame>up to 18 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>up to 24 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TKI alone until rapid progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TKI combined with investigator's choice of chemotherapy regimen and subsequent line of treatment until rapid progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGFR tyrosine kinase inhibitor</intervention_name>
    <description>Arm A</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>EGFR TKI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGFR tyrosine kinase inhibitor with chemotherapy</intervention_name>
    <description>Arm B</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>EGFR TKI with chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Patient who was confirmed stage IV NSCLC by pathologic histology or cytology. Males or&#xD;
        females aged ≥18 years, &lt; 75 years. Eastern Cooperative Oncology Group (ECOG) performance&#xD;
        status 0-2. Life expectancy ≥12 weeks.&#xD;
&#xD;
        Males and females should be contraceptive during the period of the trial until 8 weeks&#xD;
        after the last administration of the drug.&#xD;
&#xD;
        Definition of gradual progression:&#xD;
&#xD;
          1. Slow PD (6 months of partial response/stable disease),&#xD;
&#xD;
          2. Asymptomatic minimal PD,&#xD;
&#xD;
          3. New brain metastasis controlled locally. Patients with asymptomatic, treated brain&#xD;
             metastases are eligible for trial participation.&#xD;
&#xD;
        Adequate bone marrow, renal, and liver function are required. Able to comply with the&#xD;
        required protocol and follow-up procedures, and able to receive oral medications.&#xD;
&#xD;
        Institutional review board-approved informed consent will be obtained for every patient&#xD;
        before initiation of any trial-specific procedure or treatment.&#xD;
&#xD;
        Exclusion criteria： Any unstable systemic disease (including active infection, uncontrolled&#xD;
        hypertension, unstable angina, congestive heart failure, myocardial infarction within the&#xD;
        previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or&#xD;
        metabolic disease).&#xD;
&#xD;
        Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome,&#xD;
        or inability to take oral medication, or have active peptic ulcer disease.&#xD;
&#xD;
        Female subjects should not be pregnant or breast-feeding. Adequate hematological function:&#xD;
        Absolute neutrophil count (ANC) ≥1.5 x 109/L, and Platelet count ≥100 x 109/L.&#xD;
&#xD;
        Adequate renal function: Serum creatinine ≤ 1.5 x ULN, or ≥ 50 ml/min. Adequate liver&#xD;
        function :Total bilirubin £ 1.5 x upper limit of normal (ULN) and Alanine Aminotransferase&#xD;
        (ALT )and Aspartate Aminotransferase (AST )&lt; 2.5 x ULN in the absence of liver metastases,&#xD;
        or &lt; 5 x ULN in case of liver metastases.&#xD;
&#xD;
        Patient assessed by the investigator to be unable or unwilling to comply with the&#xD;
        requirements of the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Qiong Zhao</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiong Zhao, PhD</last_name>
      <phone>0571-87236802</phone>
      <email>doczq.2008@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>November 24, 2013</study_first_submitted>
  <study_first_submitted_qc>November 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2013</study_first_posted>
  <last_update_submitted>December 19, 2013</last_update_submitted>
  <last_update_submitted_qc>December 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Qiong Zhao</investigator_full_name>
    <investigator_title>Chief of Department of Thoracic Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

